RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities. @RheumNow #EULAR2025 #OP0197

Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions In ACPA+ RA pts for each 10% increase in strain, 7% increase in SJC44 and 5% MRI inflammation POS0166 #EULAR2025 @RheumNow https://t.co/jwpi7S8JTW

• https://x.com/AurelieRheumo/status/1933107796003959214/photo/1

We should address patients anxiety at RA diagnosis: cohort 250+ newly diagnosed RA pts -49% reported anxiety -41% by 3 months Anxiety asso w/ CDAI, PROs and 3-5 fold increase in prescription of bio/tsDMARDs Analysis reasonably adjusted POS0163 #EULAR2025 @RheumNow https://t.co/2gejEkRQhO

• https://x.com/AurelieRheumo/status/1933108806050861405/photo/1

BioDMARDs reduce polyimmunity in RA Danish Registry based cohort study 5 yrs follow up 25000+ pts Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group HR 0.74 Most frequent autoimmune thyroid disease POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs

• https://x.com/AurelieRheumo/status/1933110415896039688/photo/1

There is still hope for vagal nerve stimulation in RA! RCT RESET-RA 240+pts multibioIR Implantable cervical device Meets Primary endpoint ACR 20 wk12 Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham EULAR Good response 61% vs 42% sham Wk 12 SAE rate 1.7% #OP0190 #EULAR2025 https://t.co/DCON01XXgd

• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1
• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1
• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1
• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1

Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN

Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17, M-CSF induced hepcidin via JAK-STAT pathway. Hepcidin reduced osteoclastogenesis but correlated with synovial neutrophils and CXCL1 induction. Functional dual https://t.co/ZjUtTYPre8

• https://x.com/synovialjoints/status/1932919681989443588/photo/1

VEGF-Grab (PB101/PB102), dual VEGF/PlGF decoy receptor, inhibited angiogenesis, RA-FLS invasion, and Th17 cell differentiation in RA and MS models. PB102 reduced IL-17 and GM-CSF co-expressing Th17 cells, suppressed pannus and joint destruction in CIA, and outperformed IFN-β in https://t.co/qhVRYT4RbK

• https://x.com/synovialjoints/status/1932920559576232224/photo/1

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/xbgJHhPqcq

📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA. Risk ↑ with RF/CCP+, nodules (HR 2.9), BMI ≥30 (HR 1.9), & biologic use in year 1 (HR 2.4–2.9). Remission = ↓ PE risk (HR 0.47) 📍OP0070 @RheumNow #EULAR2025

POS0627: RA patients aged ≥90 yrs can benefit from biologics/JAKi! In 3,600 pts, 84% of those ≥90 achieved low disease activity, 71% were on JAKi. But serious infections occurred in 21%—mostly pneumonia. Use w/caution in the oldest-old. #EULAR2025 @rheumnow

#Probiotics +#methotrexate giving far more #remission in #rheumatoid #arthritis than #MTX alone? Seems fishy…. oops - #fish #oil #omega3 #fatty #acids do work! not sure re the huge benefit of ‘immunebiotics’ #EULAR2025 @RheumNow @eular_org abst#POS0483 https://t.co/STQuaOkBcY

• https://twitter.com/janetbirdope/status/1932567045297623357

In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007) #EULAR2025 @RheumNow Abstract#OP0069 https://t.co/jWI6tvri8O

• https://x.com/JihaRheum/status/1932820564793831909/photo/1

Can RA be intercepted? In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles. Abstract#OP0004 @RheumNow #EULAR2025 https://t.co/N7YwtYod8w

• https://x.com/JihaRheum/status/1932820871367864579/photo/1